HIF1A and metastatic melanoma: The study of Kluza et al. showed the preclinical validation that HIF-1/PDK3 bioenergetic route can be a new target for therapy in metastatic melanoma and can be used in patients that achieve BRAF-therapy resistance (79); further drugs aiming these targets (e.g., dichloroacetate, elesclomol) entered clinical trials (80).